menopause. Menopausal and female climacteric states
Conditions
Interventions
Intervention 1: group A: Continuous conjugated estrogen (CE) 0.625mg plus medroxyprogestrone acetate (MPA) 2.5mg. Intervention 2: group B: Tibolone 2.5mg/day. Intervention 3: group C (placebo group):C
Treatment - Drugs
Placebo
group A: Continuous conjugated estrogen (CE) 0.625mg plus medroxyprogestrone acetate (MPA) 2.5mg
group B: Tibolone 2.5mg/day
group C (placebo group):Ca-D (500 mg +200 IU)
Sponsors
Tarbiat Maodares University
Eligibility
Sex/Gender
Female
Age
45 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: married, menopause after 40 years old and 12 months amenorrhea or 6 month amenorrhea and serum Estradiol less than 50 pg/dl. Exclusion criteria: any history of active hepatitis, cardiovascular, inflamation disease (infectious or uninfectious), thoromboambolic or cerebrovascular disorder, psychosis, hyperlipidemia, history of chemotherapy or radiation, HRT treatment in previous 6 months, use of vitamine E, fluxitine, soymenopause,propranolol and another herbal or chemical druge, smoking, alchol or addiction
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Climacteric symptom. Timepoint: 6 month. Method of measurement: Greene Climacteric Scale & Female Sexual Function Index. | — |
Secondary
| Measure | Time frame |
|---|---|
| Sex hormone status & sex hormone-binding globulin (SHBG). Timepoint: 6 month. Method of measurement: biochemistry. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSedigheh Moghasemi
Golestan University of Medical Sciences
Outcome results
None listed